<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887198</url>
  </required_header>
  <id_info>
    <org_study_id>CR016927</org_study_id>
    <secondary_id>COU-AA-302</secondary_id>
    <secondary_id>2008-008004-41</secondary_id>
    <nct_id>NCT00887198</nct_id>
  </id_info>
  <brief_title>Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus
      prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with
      metastatic castration-resistant prostate cancer (CRPC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (individuals will be assigned by chance to study treatments),
      double-blind (individuals and study personnel will not know the identity of study
      treatments), placebo (an inactive substance that is compared with a drug to test whether the
      drug has a real effect in a clinical trial)-controlled study in approximately 1,000 medically
      or surgically castrated male patients with metastatic CRPC who have shown tumor progression
      and are asymptomatic or mildly symptomatic. The study period will consist of screening,
      treatment, and follow-up phases. Patients will receive study treatment (abiraterone acetate
      or placebo) plus prednisone until radiographic progression of disease and/or unequivocal
      clinical progression. Efficacy evaluations will be performed throughout the treatment period
      and safety will be assessed until 30 days after the last dose of abiraterone acetate.
      throughout the study. Follow-up will continue for up to 60 months (5 years) or until the
      patient dies, is lost to follow-up, or withdraws informed consent. At the interim analysis of
      overall survival (OS; 43% of death events), the independent data monitoring committee (IDMC)
      reviewed the efficacy and safety data and concluded that all of the data pointed to a
      significant advantage for patients in one arm of the study compared with the other arm
      thereby unanimously recommending unblinding the study and allowing crossover from the placebo
      arm to active therapy. Patients currently receiving placebo will be offered crossover therapy
      to abiraterone acetate. Treatment for patients who were originally randomized to the
      abiraterone acetate treatment group will not change. Patients will be discontinued from long
      term follow-up at the time of the Clinical Cut-Off Date for Final Analysis (CCO-FA); however,
      patients still receiving treatment with abiraterone acetate at the CCO-FA will be offered to
      receive continued treatment for an additional period of up to 3 years or until disease
      progression or unacceptable toxicity. For these patients, safety assessment will be performed
      while continuing treatment, and for 30 days after the last dose of abiraterone acetate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2009</start_date>
  <completion_date type="Actual">May 25, 2017</completion_date>
  <primary_completion_date type="Actual">March 31, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization (Day 1) up to end of study (Month 60)</time_frame>
    <description>Overall survival is defined as the time from randomization to date of death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic Progression-free Survival (rPFS)</measure>
    <time_frame>From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)</time_frame>
    <description>The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (&gt;=) 2 new lesions compared to baseline was observed in less than (&lt;) 12 weeks from randomization and was confirmed by a second bone scan taken &gt;=6 weeks later showing &gt;=2 additional new lesions (a total of &gt;=4 new lesions compared to baseline), b) the first bone scan with &gt;=2 new lesions compared to baseline was observed in &gt;=12 weeks from randomization and the new lesions were verified on the next bone scan &gt;=6 weeks later (a total of &gt;=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Opiate Use for Prostate Cancer Pain</measure>
    <time_frame>From randomization (Day 1) up to first opiate use or end of study (Month 60)</time_frame>
    <description>The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Initiation of Cytotoxic Chemotherapy</measure>
    <time_frame>From randomization (Day 1) up to initiation of cytotoxic chemotherapy or cutoff date (Month 18)</time_frame>
    <description>The time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. Participants who had no cytotoxic chemotherapy administration at the time of analysis were censored at the last known date when no cytotoxic chemotherapy was administered. Participants with no assessment were censored at the date of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by &gt;=1 Point</measure>
    <time_frame>From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)</time_frame>
    <description>The time interval from the date of randomization to the first date at which there was at least a 1 grade change (worsening) in the ECOG performance status grade. Participants who had no deterioration in ECOG performance status grade at the time of the analysis were censored at the last known date of no deterioration. ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead. Participants with no assessment were censored at the date of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Prostate-specific Antigen (PSA) Progression</measure>
    <time_frame>From randomization (Day 1) up to date of PSA progerssion or cutoff date (Month 18)</time_frame>
    <description>The time interval from the date of randomization to the date of PSA progression as defined in the protocol-specific prostate cancer Working Group 2 (PCWG2) criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanogram/milliliter ((ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks. Participants who had no PSA progression at the time of the analysis were censored at the last known date of no PSA progression. Participants with no on-study PSA assessment or no baseline PSA assessment were censored at the date of randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>From first dose of study drug up to 30 days after the last dose of study drug</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Plasma Concentrations of Abiraterone</measure>
    <time_frame>Up to Cycle 5, Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentrations of Abiraterone</measure>
    <time_frame>Up to Cycle 5, Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to Time the Last Quantifiable Concentration of Abiraterone (AUC[0-infinity])</measure>
    <time_frame>Up to Cycle 5, Day 1</time_frame>
    <description>The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (t1/2)</measure>
    <time_frame>Up to Cycle 5, Day 1</time_frame>
    <description>The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1088</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo + prednisone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abiraterone + prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abiraterone acetate plus prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone acetate</intervention_name>
    <description>1000 mg per day (4 x 250-mg tablets) taken orally.</description>
    <arm_group_label>Abiraterone + prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 placebo tablets per day taken orally.</description>
    <arm_group_label>Placebo + prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>5 mg tablet orally twice daily.</description>
    <arm_group_label>Placebo + prednisone</arm_group_label>
    <arm_group_label>Abiraterone + prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic castration-resistant prostate cancer (CRPC)

          -  Previous anti-androgen therapy and progression after withdrawal

          -  ECOG performance status of either 0 or 1

          -  Medical or surgical castration with testosterone less than 50 ng/dL

          -  Life expectancy of at least 6 months

        Exclusion Criteria:

          -  Prior cytotoxic chemotherapy or biologic therapy for CRPC

          -  Prior ketoconazole for prostate cancer

          -  Known brain metastasis or visceral organ metastasis

          -  Use of opiate analgesics for cancer-related pain, including codeine and
             dextropropoxyphene, currently or anytime within 4 weeks of Cycle 1 Day 1
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marina Del Rey</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Footscray</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garran</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Geelong</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hornsby</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kogarah</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurralta Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lismore</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malvern</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southport</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Subiaco</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven Belgie</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon Cedex 03</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 15</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours, Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kempen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larisa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander N/A</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malmö N/A</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Växjö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Whitchurch</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
    <country>Niger</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <results_first_submitted>March 30, 2015</results_first_submitted>
  <results_first_submitted_qc>March 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2015</results_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Abiraterone acetate</keyword>
  <keyword>CB7630</keyword>
  <keyword>CRPC</keyword>
  <keyword>Metastatic castration-resistant prostate cancer</keyword>
  <keyword>hormone refractory prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Abiraterone Acetate</title>
          <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="546"/>
                <participants group_id="P2" count="542"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="384"/>
                <participants group_id="P2" count="431"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="352"/>
                <participants group_id="P2" count="387"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.</population>
      <group_list>
        <group group_id="B1">
          <title>Abiraterone Acetate</title>
          <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="546"/>
            <count group_id="B2" value="542"/>
            <count group_id="B3" value="1088"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.5" spread="8.8"/>
                    <measurement group_id="B2" value="70.1" spread="8.72"/>
                    <measurement group_id="B3" value="70.3" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="546"/>
                    <measurement group_id="B2" value="542"/>
                    <measurement group_id="B3" value="1088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall survival is defined as the time from randomization to date of death from any cause.</description>
        <time_frame>From randomization (Day 1) up to end of study (Month 60)</time_frame>
        <population>Intent-to-treat (ITT) population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Abiraterone Acetate</title>
            <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is defined as the time from randomization to date of death from any cause.</description>
          <population>Intent-to-treat (ITT) population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.66" lower_limit="32.72" upper_limit="36.80"/>
                    <measurement group_id="O2" value="30.29" lower_limit="28.65" upper_limit="33.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Radiographic Progression-free Survival (rPFS)</title>
        <description>The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (&gt;=) 2 new lesions compared to baseline was observed in less than (&lt;) 12 weeks from randomization and was confirmed by a second bone scan taken &gt;=6 weeks later showing &gt;=2 additional new lesions (a total of &gt;=4 new lesions compared to baseline), b) the first bone scan with &gt;=2 new lesions compared to baseline was observed in &gt;=12 weeks from randomization and the new lesions were verified on the next bone scan &gt;=6 weeks later (a total of &gt;=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause.</description>
        <time_frame>From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)</time_frame>
        <population>ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Abiraterone Acetate</title>
            <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiographic Progression-free Survival (rPFS)</title>
          <description>The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (&gt;=) 2 new lesions compared to baseline was observed in less than (&lt;) 12 weeks from randomization and was confirmed by a second bone scan taken &gt;=6 weeks later showing &gt;=2 additional new lesions (a total of &gt;=4 new lesions compared to baseline), b) the first bone scan with &gt;=2 new lesions compared to baseline was observed in &gt;=12 weeks from randomization and the new lesions were verified on the next bone scan &gt;=6 weeks later (a total of &gt;=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause.</description>
          <population>ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="11.66">Data was not estimable due to insufficient number of participants who had the event.</measurement>
                    <measurement group_id="O2" value="8.28" lower_limit="8.12" upper_limit="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Opiate Use for Prostate Cancer Pain</title>
        <description>The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization.</description>
        <time_frame>From randomization (Day 1) up to first opiate use or end of study (Month 60)</time_frame>
        <population>ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Abiraterone Acetate</title>
            <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Opiate Use for Prostate Cancer Pain</title>
          <description>The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization.</description>
          <population>ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.38" lower_limit="30.23" upper_limit="39.75"/>
                    <measurement group_id="O2" value="23.39" lower_limit="20.27" upper_limit="27.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Initiation of Cytotoxic Chemotherapy</title>
        <description>The time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. Participants who had no cytotoxic chemotherapy administration at the time of analysis were censored at the last known date when no cytotoxic chemotherapy was administered. Participants with no assessment were censored at the date of randomization.</description>
        <time_frame>From randomization (Day 1) up to initiation of cytotoxic chemotherapy or cutoff date (Month 18)</time_frame>
        <population>ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Abiraterone Acetate</title>
            <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Initiation of Cytotoxic Chemotherapy</title>
          <description>The time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. Participants who had no cytotoxic chemotherapy administration at the time of analysis were censored at the last known date when no cytotoxic chemotherapy was administered. Participants with no assessment were censored at the date of randomization.</description>
          <population>ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.17" lower_limit="23.26">Upper limit was not estimable due to insufficient number of participants who had the event.</measurement>
                    <measurement group_id="O2" value="16.82" lower_limit="14.55" upper_limit="19.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by &gt;=1 Point</title>
        <description>The time interval from the date of randomization to the first date at which there was at least a 1 grade change (worsening) in the ECOG performance status grade. Participants who had no deterioration in ECOG performance status grade at the time of the analysis were censored at the last known date of no deterioration. ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead. Participants with no assessment were censored at the date of randomization.</description>
        <time_frame>From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)</time_frame>
        <population>ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Abiraterone Acetate</title>
            <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by &gt;=1 Point</title>
          <description>The time interval from the date of randomization to the first date at which there was at least a 1 grade change (worsening) in the ECOG performance status grade. Participants who had no deterioration in ECOG performance status grade at the time of the analysis were censored at the last known date of no deterioration. ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead. Participants with no assessment were censored at the date of randomization.</description>
          <population>ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.29" lower_limit="11.33" upper_limit="14.29"/>
                    <measurement group_id="O2" value="10.87" lower_limit="9.49" upper_limit="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Prostate-specific Antigen (PSA) Progression</title>
        <description>The time interval from the date of randomization to the date of PSA progression as defined in the protocol-specific prostate cancer Working Group 2 (PCWG2) criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanogram/milliliter ((ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks. Participants who had no PSA progression at the time of the analysis were censored at the last known date of no PSA progression. Participants with no on-study PSA assessment or no baseline PSA assessment were censored at the date of randomization.</description>
        <time_frame>From randomization (Day 1) up to date of PSA progerssion or cutoff date (Month 18)</time_frame>
        <population>ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Abiraterone Acetate</title>
            <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Prostate-specific Antigen (PSA) Progression</title>
          <description>The time interval from the date of randomization to the date of PSA progression as defined in the protocol-specific prostate cancer Working Group 2 (PCWG2) criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanogram/milliliter ((ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks. Participants who had no PSA progression at the time of the analysis were censored at the last known date of no PSA progression. Participants with no on-study PSA assessment or no baseline PSA assessment were censored at the date of randomization.</description>
          <population>ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.07" lower_limit="8.51" upper_limit="11.24"/>
                    <measurement group_id="O2" value="5.55" lower_limit="5.39" upper_limit="5.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.</description>
        <time_frame>From first dose of study drug up to 30 days after the last dose of study drug</time_frame>
        <population>Safety analysis set included all participants in the randomized population who received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Abiraterone Acetate</title>
            <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Abiraterone Acetate</title>
            <description>Participants received initially placebo along with prednisone 5 mg tablet, orally, later on switched to 1,000 milligram (mg) abiraterone acetate tablet (as 4*250 mg tablets) along with prednisone 5 mg tablet due to disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.</description>
          <population>Safety analysis set included all participants in the randomized population who received any study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="542"/>
                <count group_id="O2" value="540"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Treatment-Emergent Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541"/>
                    <measurement group_id="O2" value="524"/>
                    <measurement group_id="O3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With Treatment-Emergent Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="148"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Plasma Concentrations of Abiraterone</title>
        <time_frame>Up to Cycle 5, Day 1</time_frame>
        <population>Data was not reported as non-compartmental analysis was not performed due to sparse sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Abiraterone Acetate</title>
            <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Concentrations of Abiraterone</title>
          <population>Data was not reported as non-compartmental analysis was not performed due to sparse sampling.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentrations of Abiraterone</title>
        <time_frame>Up to Cycle 5, Day 1</time_frame>
        <population>Data was not reported as non-compartmental analysis was not performed due to sparse sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Abiraterone Acetate</title>
            <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentrations of Abiraterone</title>
          <population>Data was not reported as non-compartmental analysis was not performed due to sparse sampling.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to Time the Last Quantifiable Concentration of Abiraterone (AUC[0-infinity])</title>
        <description>The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.</description>
        <time_frame>Up to Cycle 5, Day 1</time_frame>
        <population>Data was not reported as non-compartmental analysis was not performed due to sparse sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Abiraterone Acetate</title>
            <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to Time the Last Quantifiable Concentration of Abiraterone (AUC[0-infinity])</title>
          <description>The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.</description>
          <population>Data was not reported as non-compartmental analysis was not performed due to sparse sampling.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half-Life (t1/2)</title>
        <description>The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).</description>
        <time_frame>Up to Cycle 5, Day 1</time_frame>
        <population>Data was not reported as non-compartmental analysis was not performed due to sparse sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Abiraterone Acetate</title>
            <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-Life (t1/2)</title>
          <description>The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).</description>
          <population>Data was not reported as non-compartmental analysis was not performed due to sparse sampling.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug up to 30 days after the last dose of study drug</time_frame>
      <desc>Safety analysis set included all participants in the randomized population who received any study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Abiraterone Acetate</title>
          <description>Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.</description>
        </group>
        <group group_id="E3">
          <title>Placebo to Abiraterone Acetate</title>
          <description>Participants received initially placebo along with prednisone 5 mg tablet, orally, later on switched to 1,000 milligram (mg) abiraterone acetate tablet (as 4*250 mg tablets) along with prednisone 5 mg tablet due to disease progression.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="208" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gallbladder abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal scratch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cataract operation complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastroenteritis radiation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Narcotic intoxication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pubic rami fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Colonoscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Jaw cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell type acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of Vater</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urethral cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bladder tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Prostatic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Scrotal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tonsillar cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lentigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Aortic valve replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Chemotherapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pancreatectomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="530" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="505" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="200" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="542"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="540"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the Sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>These results are up to clinical cutoff (CCO) date (that is, 31 March 2014).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>SENIOR DIRECTOR CLINICAL RESEARCH</name_or_title>
      <organization>Janssen R&amp;D US</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

